cell culture | pharmaphorum

Skip to main content

Saturday 10 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

cell culture

R&D

pharmaphorum podcast Episode 207a, Brandon Pence

The importance of being disruption ready, with Brandon Pence

Brandon Pence, recently appointed President and COO of Fujifilm Biosciences, discusses the cell culture media industry and being disruption ready.

Partner Content

P-310 3d Cell Culture 2020 banner 350x350

Partner Content

Key Reasons to attend SMi’s 3D Cell Culture Conference 2020

Key Reasons to attend SMi’s 3D Cell Culture

Partner Content

350x350-3D-Cell-Culture-2019

Partner Content

SMi’s 3D Cell Culture announces key industry speakers and ag...

SMi's 3d Cell Culture agenda released

Events

350x350-3D-Cell-Culture-2019

Partner Content

SMi’s 3rd Annual 3D Cell Culture Conference

3D Cell Culture Conference

Events

cctb_2

Partner Content

Cell Culture and Cell Therapy: Bioprocessing Conference

Cellular therapies hold the potential to revolutionize health care for a variety of diseases.

Editor's Picks

MSD ordered to pull injectable Keytruda from sale in Europe

PhRMA sues Trump administration over GLOBE rebate scheme

UK watchdog takes first action on oral weight drug adverts

Click claims FDA okay for first-in-class schizophrenia DTx

New York declares measles outbreak a "disaster emergency"

News

Iambic prices its IPO, seeking to raise up to $160m

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company